ALPL and hypophosphatasia: While a bone-targeted recombinant TNSALP (asfotase alfa) is currently available to successfully treat severely affected pediatric HPP patients13, a thorough understanding of the broad phenotypic spectrum and pathophysiological effects of HPP on muscle, tooth and bone physiology is lacking and would prove beneficial for assessing prognosis and treatment for any given patient7.